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Background: Staphylococcus aureus is the most common and most important pathogen following knee and hip
arthroplasty procedures. Understanding the epidemiology of invasive S. aureus infections is important to quantify
this serious complication.
Methods: This nested retrospective cohort analysis included adult patients who had undergone insertion of knee
or hip prostheses with clean or clean-contaminated wound class at 11 hospitals between 2003–2006. Invasive
S. aureus infections, non-superficial incisional surgical site infections (SSIs) and blood stream infections (BSIs), were
prospectively identified following each procedure. Prevalence rates, per 100 procedures, were estimated.
Results: 13,719 prosthetic knee (62%) and hip (38%) insertion procedures were performed. Of 92 invasive S. aureus
infections identified, SSIs were more common (80%) than SSI and BSI (10%) or BSI alone (10%). The rate of invasive
S. aureus infection/100 procedures was 0.57 [95% CI: 0.43-0.73] for knee insertion and 0.83 [95% CI: 0.61-1.08] for hip
insertion. More than half (53%) were methicillin-resistant. Median time-to-onset of infection was 34 and 26 days for
knee and hip insertion, respectively. Infection was associated with higher National Healthcare Safety Network risk
index (p≤ 0.0001).
Conclusions: Post-operative invasive S. aureus infections were rare, but difficult-to-treat methicillin-resistant
infections were relatively common. Optimizing preventative efforts may greatly reduce the healthcare burden
associated with S. aureus infections.
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The impact of surgical site infections (SSIs) following
prosthesis procedures is devastating, often leading to
higher mortality, prolonged hospitalizations, frequent
readmissions, and increased costs and overall health-
care burden [1,2]. According to the United States (US)
National Healthcare Safety Network (NHSN), SSI rates
following total knee or hip arthroplasty procedures
performed from January 1, 2006 through December 31,
2008 ranged from 0.60 to 1.60 and 0.7 to 2.4 per 100
procedures, respectively, depending on patient risk level
[3]. Common factors between knee and hip procedures
found to be associated with increased risk for deep inci-
sional or organ/space SSIs include younger age, revision* Correspondence: jeanmarie_arduino@merck.com
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unless otherwise stated.procedures, longer procedure duration, severity of under-
lying illness, hospital affiliation with a medical school, bed
size >200, and trauma [4].
Staphylococcus aureus is the most common and most
important pathogen following these and other ortho-
pedic procedures. S. aureus accounts for approximately
half of the deep incisional or organ/space SSIs following
knee or hip joint arthroplasty reported to NHSN, with
methicillin-resistant S. aureus accounting for 19% of
these infections [5]. At a single-center [6], the reported
rate of SSI was 1.1 per 100 procedures following total
joint arthroplasty between 2003 to 2005, with S. aureus
accounting for more than 50% of the infections; in
addition, methicillin-resistant S. aureus (MRSA) accounted
for 21% of SSIs following total knee arthroplasty and 31%
of SSIs following total hip arthroplasty.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cardiothoracic, and plastic surgical procedures performed
in adults, we recently showed that S. aureus was the
causative pathogen for about 50% of all invasive post-
operative infections [7]. Of these S. aureus infections, SSI
were diagnosed more often (70%) versus bloodstream
infections (BSI) alone (30%). The overall rate of invasive
S. aureus infections was 0.47 infections per 100 proce-
dures (95% CI, 0.43-0.52) [7]. The rate of invasive S.
aureus infections in the orthopedic surgery subgroup
(insertion of prosthetic implants [ie, insertion of knee,
hip, or other prosthesis], open reduction and internal
fixation of a fracture, other musculoskeletal procedures,
or amputation) in the preceding study was 0.37 infections
per 100 procedures [95% CI, 0.32-0.42]. These infections
were associated with three variables included in the
NHSN risk index score: 1) American Society of Anes-
thesiologists (ASA) score; 2) wound class; and 3) length
of procedure and patient age. In addition, orthopedic
procedures involving prosthetic implants had a higher
incidence of invasive S. aureus infections, 0.68 infections
per 100 procedures (95% CI, 0.56-0.81), than the overall
orthopedic subgroup. In the current report, we describe
the incidence of invasive S. aureus SSI and BSI in the sub-
set of 13,791 surgical procedures involving knee or hip
prosthetic devices from the preceding cohort of 96,455
major surgical procedures. We also assessed potential risk
factors for S. aureus infection in this group.
Methods
Study design and population
The study design has been previously described in detail
[7]. Briefly, we previously performed a multicenter,
retrospective cohort study using validated, prospectively
collected surgical surveillance data for SSI and microbi-
ologic data for BSI from nine community hospitals and
two tertiary hospitals in North Carolina and Virginia
from 2003 to 2006. Two surgical surveillance databases
were used: the Duke Infection Control Outreach Network
(DICON) surgical database and the Duke University
Medical Center (DUMC) surgical database. These da-
tabases included operative variables such as patient
age, date of surgical procedure, type of procedure, and
NHSN risk index variables (i.e., wound class, ASA
score, and length of procedure). At each hospital, all
SSIs were prospectively identified by trained infection-
control practitioners (ICPs) using standard definitions
and methods [8]. ICPs used culture results from the
clinical microbiology laboratory, readmission flags, and
surgeon surveys to identify patients with potential
SSIs. BSI data were identified by querying microbio-
logical databases from each participating hospital. The
Duke University Health System Institutional Review
Board for Clinical Investigations (DUHS IRB) was thereview board overseeing the study, and served as the
IRB of record for the participating hospitals.
The study population comprised patients at least 18 years
of age who underwent a major surgical procedure between
January 1, 2003 through December 31, 2006 (N = 81,267
patients undergoing 96,455 surgical procedures). The
nested retrospective analysis was limited to prosthetic
surgical procedures (knee or hip insertion) with clean or
clean-contaminated wound class (N = 13,719 procedures).
Outcome measures
The primary outcome was invasive SSI and/or BSI due
to S. aureus. Invasive SSIs were defined as deep inci-
sional and organ/space SSIs diagnosed within one year
following surgery, consistent with Centers for Disease
Control and Prevention (CDC) defintions [8]. BSIs
were defined using modified CDC criteria: at least one
positive blood culture within 90 days after the procedure
for all pathogens except coagulase-negative staphylococci,
micrococci, Propionibacteria, diphtheroids, enterococci,
viridans group streptococci, and bacilli, for which at least
two positive results for cultures of blood collected during
a 48-hour period were required [9]. Other outcomes of
interest included methicillin susceptibility of S. aureus iso-
lates and time to infection.
Statistical analysis
This analysis was restricted to surgical procedures in
patients preoperatively classified as having clean or
clean-contaminated wounds. Patients could have had
more than one surgery during the study period, al-
though procedures performed after documentation of a
patient's first S. aureus infection were excluded. Infections
were attributed to the most recently performed procedure.
Procedures associated with a superficial incisional S. aureus
SSI or SSI of unknown type were also excluded.
All statistical analyses were performed using SAS soft-
ware, version 9.1 (SAS Institute, Cary, NC). All statistical
tests were 2-tailed, and a P-value of less than 0.05 was
considered significant. Incidence rates were calculated as
the number of infections per 100 surgical procedures.
Nonparametric bootstrapping was used to generate 95%
confidence intervals (CIs) for the rates. The proportions
of patients with infections due to MRSA were also calcu-
lated. Kaplan-Meier analyses were performed to com-
pute the median time between the date of the surgical
procedure and the date of onset of infection.
To identify characteristics potentially associated with
the development of invasive S. aureus infection, bivari-
able comparisons were performed between patients
who developed an invasive S. aureus infection and
those who did not. P-values were calculated using
Pearson chi-square tests for categorical variables and
the Student’s t-test for continuous variables. This
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made for multiple statistical tests, and the results
should be interpreted accordingly.
Results
Study population
A total of 13,719 prosthetic knee or hip insertion proce-
dures were performed during the study period; 8,446
(62%) involved the knee and 5,273 (38%) involved the
hip. Compared with patients who underwent prosthetic
knee insertions, patients who underwent prosthetic hip
insertions were more likely to be 60 years of age or older
(66% versus 60%, p < 0.0001); to be at community hospitals
(60% versus 53%, p < 0.0001); to have clean-contaminated
wound class (5% versus 4%, p = 0.0028); and to have more
severe disease, ASA scores of 3 or greater (56% versus 50%,
p < 0.0001) (Table 1).
Rates and characteristics of invasive S. aureus infection
S. aureus caused 92 (55%) of the 167 post-operative
invasive infections. Among the invasive S. aureus infec-
tions, SSIs were more common (80%) than SSI and BSITable 1 Procedure characteristics*
Prosth
(N=8,4
NHSN risk index 0 2,404
1 4,316
≥2 1,356
Missing 370
ASA score 1: Healthy 600
2: Mild Systemic Disease 3,622
3: Severe Systemic Disease 3,855
4: Incapacitating Disease 323
5: Dying 0
6: Emergency Care 0
Missing 46
Wound class Clean 8,142
Clean - contaminated 304
Age, median (years) 63
Age category 18-29 395
(years) 30-39 421
40-49 809
50-59 1,776
60-69 2,347
70-79 2,059
80+ 639
Hospital Community (N=9) 4,442
Type Tertiary (N=2) 4,004
*Data shown as n (%) of patients, unless otherwise indicated.(10%) or BSI alone (10%). Of the 85 post-operative infec-
tions in patients undergoing prosthetic knee insertion,
48 (56%) were invasive S. aureus infections, of which 43
were SSIs, 4 were BSIs, and 1 was a combined SSI and
BSI. Of 82 total post-operative infections in patients
undergoing prosthetic hip insertion, 44 (54%) were inva-
sive S. aureus infections, of which 31 were SSIs, 5 were
BSIs, and 8 were combined SSI and BSI (Table 2). The
overall rate of invasive S. aureus infection/100 procedures
was 0.57 [95% CI: 0.43-0.73] following prosthetic knee in-
sertion and 0.83 [95% CI: 0.61-1.08] following prosthetic
hip insertion (p = 0.06). The distribution of S. aureus in-
fection types in prosthetic knee insertion procedures (SSI
90%, BSI 8%, and SSI + BSI 2%) varied significantly
from the distribution in prosthetic hip insertion proce-
dures (SSI 70%, BSI 11%, and SSI + BSI 18%), p = 0.02.
MRSA accounted for 53% of S. aureus infections
following all procedures, 45% following prosthetic
knee insertion and 61% following prosthetic hip insertion
(p = 0.11). The median time to onset of invasive S. aureus
infection was 28 days for all procedures (interquartile
range (IQR): 17–54 days), 34 days (IQR: 18–65 days) foretic knee insertion Prosthetic hip insertion
46) (N=5,273)
(28) 1,174 (22)
(51) 2,977 (56)
(16) 984 (19)
( 4) 138 ( 3)
( 7) 131 ( 2)
(43) 2,152 (41)
(46) 2,423 (46)
( 4) 526 (10)
( 0) 1 ( 0)
( 0) 0 ( 0)
( 1) 40 ( 1)
(96) 5,029 (95)
( 4) 244 ( 5)
67
( 5) 78 ( 1)
( 5) 204 ( 4)
(10) 609 (12)
(21) 900 (17)
(28) 1,082 (21)
(24) 1,271 (24)
( 8) 1,129 (21)
(53) 3,160 (60)
(47) 2,113 (40)
Table 2 Characteristics of invasive Staphylococcus aureus Infection after orthopedic surgical procedures
Prosthetic knee insertion Prosthetic hip insertion
(N=8,446) (N=5,273)
Rate of infection
Proportion of procedures 48/8,446 44/5,273
Infections per 100 procedures (95% CI) 0.57 (0.43, 0.73) 0.83 (0.61, 1.08)
Type of infection, n (%)
Surgical site infection (SSI) 43 (90) 31 (70)
Bloodstream infection (BSI) 4 ( 8) 5 (11)
BSI and SSI 1 ( 2) 8 (18)
Time to onset of infection
Median (IQR), days 34.0 (18.5 - 65.5) 26.0 (16.0 - 40.5)
SSI, n (%) occurring within
30 days 20 (45) 27 (69)
60 days 32 (73) 35 (90)
90 days 36 (82) 39 (100)
120 days 40 (91) 39 (100)
150 days 40 (91) 39 (100)
180 days 40 (91) 39 (100)
1 year 44 (100) 39 (100)
MRSA infection
21/47 (45) 27/44 (61)
Proportion (%) of S. aureus infections*
*Excludes patients for whom sensitivity data were not available (n = 1).
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for prosthetic hip insertion. Using a year surveillance
period for SSIs, 18% (8/44) of invasive S. aureus SSIs oc-
curred more than 90 days after prosthetic knee insertions,
while all invasive S. aureus SSIs occurred within 90 days
after prosthetic hip insertions.
Patients who developed invasive S. aureus infections
had higher NHSN risk index scores than did unin-
fected surgical patients following prosthetic knee inser-
tion (p < 0.0001) and prosthetic hip insertion (p = 0.0001)
(Table 3). Patients who developed invasive S. aureus infec-
tions also had higher ASA scores and significantly longer
surgical procedure durations compared to uninfected pa-
tients. Age was not associated with the risk of developing
an invasive S. aureus infection.
Discussion
Approximately 1 million primary knee and hip arthro-
plasty procedures are performed annually in the US.
In 2010, for example, 719,000 total knee replacements
and 332,000 total hip replacements were performed
[10]. The volume of joint arthroplasty procedures is
projected to increase substantially in the United States
in the coming decades [11]. An important complica-
tion of joint arthroplasty procedures is post-surgical
infection [12], which is often caused by S. aureus.The purpose of this analysis was to determine the epi-
demiology of invasive S. aureus infections following
prosthetic knee or hip insertion procedures. We found a
slightly higher rate of invasive S. aureus infections in pa-
tients receiving prosthetic hip insertions compared to
those receiving prosthetic knee insertions (0.83 vs 0.57 per
100 procedures), although the difference was not statisti-
cally significant. NHSN risk index score, ASA score, and
procedure duration all significantly affected the rates of
postoperative staphylococcal infections for both types of
prosthetic insertion procedures. In addition, more than
half of the S. aureus infections were MRSA infections.
Our results are similar to previously published reports.
Rao and colleagues found that the overall SSI rate after
total joint arthroplasty at a single institution was 1.1 per
100 procedures, with S. aureus accounting for 53% of
SSIs following total knee arthroplasty and 65% of SSIs
following total hip arthroplasty [6]. Our results are also
consistent with national surveillance rates, in which the
deep incisional or organ/space SSI infection rates are re-
ported to range between 0.60 to 2.40 per 100 procedures
for prosthetic knee and hip insertions [3], with approxi-
mately 50% of these infections attributable to S. aureus
and 40% of the S. aureus infections caused by MRSA [5].
The CDC updated the NHSN surveillance definitions
for SSIs in January 2013. Prior to 2013, post-operative
Table 3 Comparison of patients with post-operative Staphylococcus aureus infection and uninfected patients following
orthopedic surgical procedures*
Prosthetic Knee Insertion Prosthetic Hip Insertion
S. aureus infection Uninfected S. aureus infection Uninfected
(N=48) (N=8,340) (N=44) (N=5,168)
NHSN risk index
0 5 (10) 2,395 (29) 1 ( 2) 1,170 (23)
1 19 (40) 4,268 (51) 23 (52) 2,916 (56)
≥2 22 (46) 1,311 (16) 18 (41) 947 (18)
Missing 2 ( 4) 366 ( 4) 2 ( 5) 135 ( 3)
p-value <0.0001 0.0001
ASA score
1: Healthy 1 ( 2) 599 ( 7) 0 ( 0) 131 ( 2)
2: Mild systemic disease 12 (25) 3,595 (43) 8 (18) 2,133 (41)
3: Severe systemic disease 28 (58) 3,790 (45) 28 (64) 2,359 (46)
4: Incapacitating disease 7 (15) 311 ( 4) 7 (16) 506 (10)
5: Dying 0 ( 0) 0 ( 0) 0 ( 0) 1 (<1)
6: Emergency care 0 ( 0) 0 ( 0) 0 ( 0) 0 ( 0)
Missing 0 ( 0) 45 (<1) 1 ( 2) 38 ( 1)
p-value 0.0002 0.024
Wound class
Clean 47 (98) 8,042 (96) 43 (98) 4,927 (95)
Clean - contaminated 1 ( 2) 298 ( 4) 1 ( 2) 241 ( 5)
p-value 0.58 0.45
Procedure duration
Mean (SD), minutes 158.2 (108.1) 124.7 (110.0) 169.3 (112.8) 125.5 (109.6)
p-value 0.036 0.0082
Age category (years)
18-29 1 ( 2) 393 ( 5) 1 ( 2) 77 ( 1)
30-39 2 ( 4) 418 ( 5) 1 ( 2) 203 ( 4)
40-49 8 (17) 793 ( 9) 4 ( 9) 598 (12)
50-59 12 (25) 1,752 (21) 7 (16) 883 (17)
60-69 9 (19) 2,318 (28) 8 (18) 1,060 (20)
70-79 11 (23) 2,039 (24) 6 (14) 1,250 (24)
80+ 5 (10) 627 ( 7) 17 (39) 1,097 (21)
p-value 0.46 0.17
*Data shown as n (%) of patients, unless otherwise indicated.
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thetic knee or hip insertion procedures [9]. In the new
2013 SSI definitions, the surveillance period for these
procedures has been reduced to 90 days [13]. Changing
the SSI surveillance definition from 1 year to 90 days re-
sults in an 18% decrease in the number of SSI following
prosthetic knee insertion procedures in this study. The
surveillance definitions used in estimating rates, whether
pre- or post-January 2013, will need to be accounted for
when interpreting time-trends in SSI rates [14].Our study has several limitations. First, as with the pri-
mary analysis [7], true incidence rates of post-operative
S. aureus infections were likely underestimated for the
following reasons: superficial incisional SSIs and other
invasive infections such as pneumonia were excluded;
patients who died before diagnosis of invasive infection
were not identified; and infections occurring post-discharge
from the hospital may have been under-reported [15].
To minimize the likelihood of missed SSIs, surveillance
methods for SSIs at study hospitals included flagging
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tify potential SSIs. Since BSIs were identified from the
study hospitals’ microbiology databases, only patients
with post-discharge BSIs re-admitted to the same study
hospital performing the surgical procedure would be
detected. In addition, we were unable to determine the
source of BSI (e.g., “primary” versus “secondary”). The
classification of surgery as elective or emergency was
not captured in the surveillance database. We used
clean and clean-contaminated wound class as a proxy
for elective surgery. Further, patient-level data on anti-
microbial prophylaxis prior to surgery were not available.
Finally, the generalizability of these findings is limited
since (1) all the participating hospitals are located in the
southeastern U.S., and (2) the data were collected from
2003–2006, prior to improvements in infection control
practices that have resulted in a reduction in MRSA infec-
tions nationally since 2006 [16].
Our study has several strengths. The data were from a
large, multicenter study using pre-existing, prospectively
collected surgical surveillance data for SSI and micro-
biology data for BSI. The study utilized well-defined
methods for classification of SSI according to Centers
for Disease Control and Prevention. Finally, we included
data from both community and tertiary care hospitals,
thereby increasing the generalizability of our results.
The healthcare and economic burden associated with
prosthetic joint infections are substantial. Healthcare re-
source use and cost of care are significantly increased
due to longer hospital stays, re-hospitalizations, lengthy
antibiotic treatment, further surgery (e.g., debridement,
exchange or resection arthroplasty, and amputation), re-
habilitation, outpatient and emergency visits. Treatment
costs for an infected knee or hip arthroplasty are more
than 3 times higher than the costs for primary arthro-
plasty [17-20]. Assuming an infection rate of 1.0% and a
cost of $130,000 per patient, the annual cost to the US
healthcare system for the management of SSI after total
knee arthroplasty has been estimated at ~ $2 billion [21].
Methicillin-resistant infections result in significantly
higher costs of care compared to methicillin-susceptible
infections, due to more hospital visits and longer hos-
pital stays [22]. Infectious complications of arthroplasty
also negatively impact the patients’ physical functioning
and health-related quality of life, which potentially con-
tribute to lost work productivity [2].
Conclusions
We found that patients undergoing hip and knee pros-
thetic joint surgery are at relatively high risk for S aureus
infections. The rates of these infections following joint
arthroplasty surgery were similar to the rates following
cardiac procedures (0.79 per 100 [95% CI: 0.61-0.97])
and neurosurgical procedures (0.62 per 100 [95% CI:0.53-0.72]), assessed in the same study population [7].
Moreover, approximately 50% of the infections observed
after joint arthroplasty were due to MRSA. Given the
poor outcomes and high costs associated with these in-
fections, this patient population represents a good target
for interventions to mitigate risk for invasive postopera-
tive S. aureus infections.
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